Journal
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
Volume 68, Issue 1, Pages 4-11Publisher
OXFORD UNIV PRESS
DOI: 10.1093/jac/dks354
Keywords
antimicrobial resistance; staphylococci; MRSA; coagulase-negative Staphylococcus; healthcare-associated infection
Funding
- NCATS NIH HHS [UL1 TR000124] Funding Source: Medline
- NIAID NIH HHS [K08 AI108272] Funding Source: Medline
Ask authors/readers for more resources
The oxazolidinone antibiotic linezolid has demonstrated potent antimicrobial activity against Gram-positive bacterial pathogens, including methicillin-resistant staphylococci. This article systematically reviews the published literature for reports of linezolid-resistant Staphylococcus (LRS) infections to identify epidemiological, microbiological and clinical features for these infections. Linezolid remains active against 98 of Staphylococcus, with resistance identified in 0.05 of Staphylococcus aureus and 1.4 of coagulase-negative Staphylococcus (CoNS). In all reported cases, patients were treated with linezolid prior to isolation of LRS, with mean times of 20.047.0 months for S. aureus and 11.08.0 days for CoNS. The most common mechanisms for linezolid resistance were mutation (G2576T) to the 23S rRNA (63.5 of LRSA and 60.2 of LRCoNS) or the presence of a transmissible cfr ribosomal methyltransferase (54.5 of LRSA and 15.9 of LRCoNS). The emergence of linezolid resistance in Staphylococcus poses significant challenges to the clinical treatment of infections caused by these organisms, and in particular CoNS.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available